Effect of different forms of methionine on lactational performance of dairy cows

Methionine is one of the first limiting AA in dairy cows. The use of rumen-protected Met to correct deficient diets is limited by the lack of a product that could be incorporated into a pelleted concentrate. The main objective of this trial was to test, at practical doses (approximately 10 g of absorbable Met), the efficacy of 2 forms of pelletable Met hydroxy analogs, D,L-2-hydroxy-4-(methylthio)-butanoic acid (HMB) and the isopropyl ester of HMB (HMBi), to provide Met to cows, especially for milk protein synthesis, compared with a negative control and to Smartamine M (SmM). These treatments were tested according to a 4 x 4 Latin square in 16 Holstein cows. Plasma Met concentrations were increased by 110 and 65% that of the control value after HMBi and SmM treatments, respectively. Milk protein yield increased by 32 and 41 g/d for HMBi and SmM, respectively. D,L-2-hydroxy-4-(methylthio)-butanoic acid supplementation did not improve Met availability to the cows for milk protein synthesis. The HMBi treatment induced an increase in 15:0 in milk at the expense of a general reduction in even-numbered short-and medium-chain fatty acids. Moreover, HMBi and SmM supplements led to an increase in the saturation level of C18 fatty acids consistent with the improvement of Met supply. It was concluded that HMBi is a new "rumen-protected" form of Met that can be supplied to cows integrated into pellets.